Serge Berger

Serge Berger

InvestorPlace Contributor

Serge Berger is the Head Trader and Investment Strategist for The Steady Trader.

He has been an active trader since 1998. During his career, he has been a financial analyst, dealt in fixed income instruments at JPMorgan, and was a proprietary trader in equity options and futures. Having exposure to a range of different asset classes allowed him to identify which asset classes and strategies best fit his goal of achieving consistent profits.

Over the years, he created a trading methodology that divides markets into different time frames and characters, allowing him to determine which strategies to apply in which situations without emotion. By focusing on only the highest probability trading setups, Serge maximizes overall profitability and minimizes stress and volatility.

Follow him on Twitter via @SteadyTrader.

Recent Articles

10 Blue-Chip Stock Charts to Watch in Q2

By Serge Berger, InvestorPlace Contributor

These 10 stock charts show companies that either will be sensitive to a broader downturn, or have come across a major area of resistance. Watch them closely.

First Solar, Inc.: Get Ready to Jump Into FSLR

By Serge Berger, InvestorPlace Contributor

First Solar's (FSLR) relative resiliency in recent months is telling. If this continues, this could lead to a nice bullish trading opportunity in First Solar stock.

Freeport-McMoRan Inc: FCX Stock Could Drop 20%

By Serge Berger, InvestorPlace Contributor

After a 200% rally, Freeport (FCX) might finally have slipped into a better consolidation mode. Traders, seize the short opportunity in FCX stock.

Tesla Motors Inc: Here’s Where You Should Buy TSLA Stock Again

By Serge Berger, InvestorPlace Contributor

Tesla stock has pulled off a sharp V-shaped reversal of late -- an awfully bullish sign. While TSLA is overbought in the near-term, you should buy the dips.

Gilead Sciences, Inc.: GILD Could Squeeze the Bears From Here

By Serge Berger, InvestorPlace Contributor

Gilead Sciences enjoyed a rally Monday along with the rest of the biotech sector. This breakout could be followed up by a short squeeze in GILD stock.

Load More